StockNews.AI
OSUR
StockNews.AI
148 days

OraSure Announces $40 Million Stock Repurchase Program

1. OraSure authorizes $40 million stock buyback over 24 months to enhance shareholder value. 2. The buyback will be funded from cash on hand, indicating strong liquidity. 3. Management will determine the timing and method of share repurchases. 4. This repurchase plan may increase stock demand and support OSUR's market price. 5. Forward-looking statements indicate potential risks in stock price fluctuations.

4m saved
Insight
Article

FAQ

Why Bullish?

Stock buybacks typically signal confidence in a company's value. Historical cases show stock prices often rise following similar announcements.

How important is it?

The stock buyback reflects financial strength and could enhance investor confidence, influencing stock price positively.

Why Short Term?

Immediate buybacks may lead to a quicker positive impact on stock prices, compared to longer-term strategic impacts.

Related Companies

AAPLMSFTAMZN
March 24, 2025 07:30 ET  | Source: OraSure Technologies, Inc. BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. The amount and timing of share repurchases will be determined by Management at its discretion. The repurchase program may be modified, suspended, or discontinued at any time at the Company’s discretion without prior notice. About OraSure Technologies, Inc. OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure, please visit www.orasure.com Forward Looking StatementsThis Press Release contains certain “forward-looking statements” within the meaning of the Federal securities laws, including with respect to the Stock Repurchase Plan and the factors that will impact the amount and timing of purchases, if any, thereunder. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to, changes in price and volume and the volatility of the Common Stock and the other risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s subsequent filings with the SEC. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Related News